Searching for treatments for non-G12C-KRAS mutant cancers |
| |
| Authors: | Christina Guo Udai Banerji |
| |
| Affiliation: | 1.The Institute of Cancer Research, London, UK ;2.The Royal Marsden Hospital NHS Foundation Trust, London, UK |
| |
| Abstract: | ![]()
KRAS mutations drive a wide variety of cancers. Drugs targeting the protein product of KRASG12C mutations are currently being evaluated show preliminary efficacy in clinical trials. A clinical trial of VS-6766, a dual RAF–MEK inhibitor, has reported early single agent activity in non-G12C mutated KRAS driven cancers.Subject terms: Drug development, Medical research |
| |
| Keywords: | |
|
|
